ArticleAnnals of intensive care2023
Assessment of the relative benefits of monotherapy and combination therapy approaches to the treatment of hospital-acquired Stenotrophomonas maltophilia pneumonia: a multicenter, observational, real-world study.
Article in Annals of intensive care, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Treatment Patterns and Clinical Outcomes in Children withMicroorganisms · 2026Article
- Association between antimicrobial regimens and 28-day mortality in patients withMicrobiology spectrum · 2026Article
- Risk factors and outcomes associated with difficult-to-treat resistance inEpidemiology and infection · 2026Article
- Treatment outcomes of combination versus monotherapy inAntimicrobial agents and chemotherapy · 2026Article
- Are two really better than one? A retrospective study comparing monotherapy versus combination therapy forMicrobiology spectrum · 2026Article
- Risk Factors Associated with Mortality in Nosocomial Stenotrophomonas maltophilia Pneumonia: A Single-Center Retrospective Study.Mediterranean journal of hematology and infectious diseases · 2026Article
- Article
- Clinical presentation and outcomes of bloodstream infection with intrinsically carbapenem-resistant non-fermenting gram-negative organisms: Stenotrophomonas maltophilia, Elizabethkingia spp. and Chryseobacterium spp. in Singapore, from 2012 to 2024.BMC infectious diseases · 2025Article
- Activity of Aztreonam-avibactam and other β-lactamase inhibitor combinations against Gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2020-2022).BMC pulmonary medicine · 2025Article
- Epidemiology and Antimicrobial Resistance of Stenotrophomonas maltophilia in China, 2014-2021.Infectious diseases and therapy · 2025Article
- Clinical characteristics and genome epidemiology of Stenotrophomonas maltophilia in Japan.The Journal of antimicrobial chemotherapy · 2024Article
- Correlation between Stenotrophomonas maltophilia incidence and systemic antibiotic use: A 10-year retrospective, observational study in Hungary.European journal of microbiology & immunology · 2024Article
- Inhaled Levofloxacin in a Combination Regimen forOpen respiratory archivesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
purposeStenotrophomonas maltophilia is a Gram-negative pathogen that most commonly causes hospital-acquired infections that can be extremely challenging to treat, contributing to underrecognized mortality throughout the world. The relative benefits of monotherapy as compared to combination therapy in patients diagnosed with S. maltophilia pneumonia, however, have yet to be established.
methodsData from 307 patients diagnosed with S. maltophilia hospital-acquired pneumonia (HAP) across four Chinese teaching hospitals from 2016 to 2022 were retrospectively analyzed.
resultsOf the analyzed patients, 55.7% (171/307) were administered combination definitive therapy, with a 30-day all-cause mortality rate of 41.0% (126/307). A propensity score weighting analysis revealed that compared with monotherapy, combination definitive therapy was associated with a comparable 30-day mortality risk in the overall patient cohort (OR 1.124, 95% CI 0.707-1.786, P = 0.622), immunocompetent patients (OR 1.349, 95% CI 0.712-2.554, P = 0.359), and patients with APACHE II scores < 15 (OR 2.357, 95% CI 0.820-6.677, P = 0.111), whereas it was associated with a decreased risk of death in immunocompromised patients (OR 0.404, 95% CI .170-0.962, P = 0.041) and individuals with APACHE II scores ≥ 15 (OR 0.494, 95% CI 0.256-0.951, P = 0.035).
conclusionThe present data suggest that when treating S. maltophilia-HAP, immunocompromised patients and individuals with APACHE II scores ≥ 15 may potentially benefit from combination therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.